Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline for Relapse Prevention After Ketamine in Depression
NCT01809340Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2013
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of minocycline in major depressive disorder (MDD) and Bipolar II disorder (BP-II) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of patients who survive relapse-free at Day 54. Started Jun 2013; status: terminated.
02
Drugs
minocycline
03
Conditions
major depressive disorder (MDD)Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on NCT01809340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01809340.